

10583094      mm/dd/yyyy>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	19	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	20	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	21	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	22	JUL 14	CA/CAPLUS to be enhanced with new citing references features
NEWS	23	JUL 16	GBFULL adds patent backfile data to 1855
NEWS EXPRESS	MAY 26 09	CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.	

10583094        mm/dd/yyyy>

NEWS HOURS       STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN       Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:23:16 ON 20 JUL 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:23:37 ON 20 JUL 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUL 2009 HIGHEST RN 1164451-20-0  
DICTIONARY FILE UPDATES: 17 JUL 2009 HIGHEST RN 1164451-20-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\105830942.str

10583094

mm/dd/yyyy>



chain nodes :

7 8 14 15 22 23 24

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 16 17 18 19 20 21

chain bonds :

6-7 7-8 8-9 8-22 13-14 14-15 14-23 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13 16-17 16-21 17-18  
18-19 19-20 20-21

exact/norm bonds :

6-7 7-8 8-9 8-22 9-10 9-13 14-15 14-23 15-16

exact bonds :

10-11 11-12 12-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :

containing 1 : 9 : 16 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:CLASS 23:CLASS 24:CLASS 25:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



10583094 mm/dd/yyyy>

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:23:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 269 TO ITERATE

100.0% PROCESSED 269 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 4396 TO 6364

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:24:03 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4965 TO ITERATE

100.0% PROCESSED 4965 ITERATIONS

58 ANSWERS

SEARCH TIME: 00.00.01

L3 58 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 08:24:09 ON 20 JUL 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2009 VOL 151 ISS 4

FILE LAST UPDATED: 19 Jul 2009 (20090719/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

10583094        mm/dd/yyyy>

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s l3

L4                2 L3

=> d ibib abs hitstr tot

10583094


mm/dd/yyyy&gt;

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:564637 CAPLUS  
DOCUMENT NUMBER: 143:97636  
TITLE: Synthesis of prolinylarylacetamides as coagulation factor Xa inhibitors for use in the prevention or treatment of thromboembolic diseases or tumors  
INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 65 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058917	A1	20050630	WO 2004-EP13509	20041126
W1: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CP, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KG, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10358814	A1	20050721	DE 2003-10358814	20031216
AU 2004299197	A1	20050630	AU 2004-299197	20041126
CA 2549589	A1	20050630	CA 2004-2549589	20041126
EP 1697318	A1	20060906	EP 2004-820404	20041126
EP 1697318	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1894210	A	20070110	CN 2004-80037698	20041126
BR 2004017630	A	20070327	BR 2004-17630	20041126
JP 2007513988	T	20070531	JP 2006-544256	20041126
AT 406350	T	20080915	AT 2004-820404	20041126
ES 2310772	T3	20090116	ES 2004-820404	20041126
IN 2006KN01579	A	20070504	IN 2006-KN1579	20060608
MX 2006006740	A	20060818	MX 2006-6740	20060614
KR 2006113729	A	20061102	KR 2006-711704	20060614
US 20070185189	A1	20070909	US 2006-583094	20060615
ZA 2006005841	A	20071031	ZA 2006-5841	20060714
PRIORITY APPLN. INFO.:			DE 2003-10358814	A 20031216
			WO 2004-EP13509	W 20041126

OTHER SOURCE(S): MARPAT 143:97636  
GI

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




AB Title compds., e.g. (I), are claimed as inhibitors of coagulation factor Xa and are claimed for use for the prophylaxis and/or therapy of thromboembolic diseases and in the treatment of tumors, as well as kits containing the compds. of interest. Thus, the title compds. were prepared, e.g., by condensation of (2R,4R)-1-(4-chlorophenylcarbamoyl)-4-hydroxyproline and N-(4-aminophenyl)-2-dimethylamino-N-Me acetamide in DMF using N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride as condensing agent. In pharmacol. testing, I had receptor affinity IC50 values of 17.0 nM and 25.0 M using FXa and TF/FVIIa receptors, resp. (no details given). Various formulations for administering the title compds. therapeutically are given.

IT 855855-29-7P 855855-32-2P  
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

inhibitors for prevention or treatment of thromboembolic diseases or tumors

RN 855855-29-7 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(methylamino)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 855855-32-2 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(2-chloroacetyl)methylamino]phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 855855-20-8P 855855-21-9P 855855-22-0P  
855855-23-1P 855855-24-2P 855855-25-3P  
855855-26-4P 855855-27-5P 855855-28-6P  
855855-30-0P 855855-31-1P 855855-33-3P  
855855-34-4P 855855-35-5P 855855-36-6P  
855855-37-7P 855855-38-8P 855855-39-9P  
855855-40-2P 855855-41-3P

R1: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of prolinylarylacetamides as coagulation factor Xa inhibitors)

for prevention or treatment of thromboembolic diseases or tumors)

RN 855855-20-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2-(dimethylamino)acetyl)methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 855855-21-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(2-(butylmethylamino)acetyl)methylamino]phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 855855-22-0 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(methyl[2-(4-morpholinyl)acetyl]amino]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-23-1 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2-(4-hydroxy-1-piperidinyl)acetyl)methylamino]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10583094

mm/dd/yyyy&gt;


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 RN 855855-24-2 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[2-(2,6-dimethyl-4-morpholinyl)acetyl]methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-25-3 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[2-(3-(cyclohexylmethyl)-1-piperidinyl)acetyl]methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B


-Cl

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 855855-30-0 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[[2-(acetyloxy)acetyl]methylamino]phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-31-1 CAPLUS  
 CN L-Leucine, N-[2-[[4-[[[(2R,4R)-1-[[4-(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]phenyl]methylamino]-2-oxoethyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 855855-26-4 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[2-(diethylamino)acetyl]methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-27-5 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[2-(ethylmethylamino)acetyl]methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-28-6 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[methyl[2-(2-methyl-1H-imidazol-1-yl)acetyl]amino]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.

-Cl

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 855855-33-3 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[2-(ethylamino)acetyl]methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-34-4 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[2-(cyclohexylamino)acetyl]methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 855855-35-5 CAPLUS  
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[methyl[2-(methylamino)acetyl]amino]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


10583094 mm/dd/yyyy>

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 855855-36-6 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-([methyl(1-methylethyl)amino]acetyl)amino]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 855855-37-7 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-([2-[(1,1-dimethylethyl)amino]acetyl)methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 855855-40-2 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2-methoxyacetyl)methylamino]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 855855-41-3 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2-ethoxyacetyl)methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 855855-38-8 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2-(cyclopentylamino)acetyl)methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-39-9 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2-(cyclopropylmethyl)amino]acetyl)methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 855855-42-4 855855-43-5 855855-45-7  
855855-46-8 855855-47-9 855855-48-0  
855855-49-1  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Preparation of prolinylarylacetamides as coagulation factor Xa inhibitors for prevention or treatment of thromboembolic diseases or tumors)


RN 855855-42-4 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(2-(dimethylamino)acetyl)methylamino]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-43-5 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2-(dimethylamino)acetyl)methylamino]-2-fluorophenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 855855-45-7 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2-ethoxyacetyl)methylamino]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10583094 mm/dd/yyyy>

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 855855-46-8 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-methyl(2-propoxyacetyl)amino]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 855855-47-9 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(2-butoxyacetyl)methylamino]phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 855855-48-0 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-[(2-methoxyacetyl)methylamino]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855855-49-1 CAPLUS  
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2-methoxyacetyl)methylamino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:434528 CAPLUS  
DOCUMENT NUMBER: 139:6763  
TITLE: Preparation of pyrrolidinedicarboxamides and related compounds as inhibitors of factor Xa useful for thrombotic disorders  
INVENTOR(S): Bigge, Christopher Franklin; Dudley, Danette Andrea; Edmunds, Jeremy John; Van Huis, Chad Alan; Casimiro-Garcia, Agustin; Filipinski, Kevin James; Kohrt, Jeffrey Thomas  
PATENT ASSIGNEE(S): Warner-Lambert Company L.L.C., USA  
SOURCE: PCT Int. Appl., 389 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045912	A1	20030605	WO 2002-1B4757	20021114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030162787	A1	20030828	US 2002-278643	20021023
US 7030141	B2	20060418		
CA 2468715	A1	20030605	CA 2002-2468715	20021114
AU 2002365313	A1	20030610	AU 2002-365313	20021114
AU 2002365313	B2	20080306		
BR 2002014519	A	20041013	BR 2002-14519	20021114
EP 1465864	A1	20041013	EP 2002-803885	20021114
EP 1465864	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, FO, MF, CY, AL, TR, BG, CZ, EE, SK				
CN 1582274	A	20050216	CN 2002-823837	20021114
HU 2004002529	A2	20050329	HU 2004-2529	20021114
JP 2005515985	T	20050602	JP 2003-547364	20021114
JP 4238135	B2	20090311		
AT 320414	T	20060415	AT 2002-803885	20021114
EP 1671949	A2	20060621	EP 2006-110738	20021114
EP 1671949	A3	20060719		
EP 1671949	B1	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, FO, MF, CY, AL, TR, BG, CZ, EE, SK				
ES 2259113	T3	20060916	ES 2002-803885	20021114
NZ 532384	A	20061027	NZ 2002-532384	20021114
AP 1744	A	20070630	AP 2004-3035	20021114
AT 402148	T	20080815	AT 2006-110738	20021114
ES 2308653	T3	20081201	ES 2006-110738	20021114
MX 2004003606	A	20040727	MX 2004-3606	20040416
IN 2004DN1062	A	20090522	IN 2004-DN1062	20040421
ZA 2004004085	A	20050905	ZA 2004-4085	20040525

10583094 mm/dd/yyyy&gt;

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

NO 2004002270	A	20040601	NO 2004-2270	20040601
NO 327006	B1	20090406		
US 20050267118	A1	20051201	US 2004-17598	20041220
US 7407972	B2	20080805		
US 20050250815	A1	20051110	US 2005-108582	20050418
US 7407974	B2	20080805		
US 20060264626	A1	20061123	US 2006-461859	20060802
US 20080287674	A1	20081120	US 2008-147038	20080626
PRIORITY APPLN. INFO.:			US 2001-334168P	P 20011129
			US 2002-384895P	P 20020531
			US 2002-278643	A3 20021023
			EP 2002-803885	A3 20021114
			WO 2002-1B33416	A 20021114
			WO 2002-1B4757	W 20021114
			US 2004-17598	A3 20041220

OTHER SOURCE(S): MARKPAT 139:6763  
GI



AB The present invention provides pyrrolidinedicarboxamides and related compds. (shown as I; variables defined below; e.g. (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]) and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compns. comprising  $\geq 1$  compds. I, processes for preparing I, and intermediates useful for preparing I.


IC50 values for inhibition of factor Xa are tabulated for >170 examples of I. About 180 example preps. of I are included. For example, (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] was prepared in 4 steps starting from Fmoc-D-Pro, SOCl<sub>2</sub>, and 4-bromo-2-fluoroaniline and involving intermediates (R)-2-[(4-bromo-2-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester, (R)-pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide, and (R)-pyrrolidine-1,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] with yields of 99, 70, 66 and 76%, resp. Four pharmaceutical formulations are described. For I: A is (un)substituted

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 536747-35-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(cyclopentylcarbonyl)amino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-23-9 CAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[[[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-3-(dimethylamino)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 536750-24-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2-oxopropyl)amino]phenyl]-4-methoxy- (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

aryl or (un)substituted monocyclic heteroaryl; B is -NHC(O)(C1-C6)alkyl, -NHC(O)(C3-C7)cycloalkyl, -NHC(O)(O)(C1-C6)alkyl, -C(O)R1, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4-C7)cycloalkenyl, unsatd. (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be (un)substituted by halo, (C1-C6)alkyl, or halo(C1-C6)alkyl, O(C1-C6), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido. C is Ph or heteroaryl, wherein Ph or heteroaryl is (un)substituted with  $\geq 1$  substituents = aryl, heteroaryl, halogen, hydroxy, -CO<sub>2</sub>R<sub>2</sub>, -COR<sub>2</sub>, -CONR<sub>2</sub>R<sub>2</sub>', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, -CH<sub>2</sub>O(C1-C6)alkyl, -CH<sub>2</sub>CO<sub>2</sub>(C1-C6)alkyl, -CH<sub>2</sub>NR<sub>2</sub>R<sub>2</sub>', or -CH<sub>2</sub>C(O)NH(C1-C6)alkyl. W1 is a satd. or unsatd., (un)substituted hydrocarbon chain or hydrocarbon-heteroatom chain having 2-6 atoms, wherein W1 connects the N atom at position 1 to the C atom at position 2 to form a four to eight membered ring; R1 is (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4-C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR<sub>3</sub>R<sub>4</sub>; R<sub>2</sub> and R<sub>2</sub>' are each independently H or (C1-C6)alkyl; and R<sub>3</sub> and R<sub>4</sub> are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxy, carbonyl, aralkoxy, carbonyl, -SO<sub>2</sub>alkyl, or joined together to form a satd. or unsatd. 3 to 7 membered ring.

IT 536747-34-9P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(4-acetylamino)phenyl]amide 1-[(4-chlorophenyl)amide] 536747-35-0P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 536748-23-9P, (2R,4R)-4-[[1-[(4-chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-dimethylaminobenzoic acid methyl ester 536750-24-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid 2-[[4-(acetylmethylamino)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide]


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)


RN 536747-34-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(acetylamino)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10583094        mm/dd/yyyy>

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.78	197.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.64	-1.64

STN INTERNATIONAL LOGOFF AT 08:24:33 ON 20 JUL 2009